BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 210 participants.

Also called NCT07755904

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 210 participants (planned count) (from the registry)
Sponsor
Braveheart Bio, Inc. (from the registry)
Registry
  • NCT NCT07755904
  • EU CT 2026-526007-30-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07755904. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-02 (actual); primary completion 2028-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy
Acronym
LIONHEART-HCM
Condition
Cardiomyopathy, Hypertrophic Obstructive
Intervention (Drug)
BHB-1893
Intervention (Drug)
Metoprolol
Lead sponsor
Braveheart Bio, Inc. (class: industry)

Record details

Record id
cardio:ct-nct07755904
Content hash
1f419ac343ecd0a96e59d201f32aa6b26280018b159831628566657cbcb789f4